India Infertility Treatments Market to Grow at Over 13% Through 2020 Says Pharmaion
BURNABY, Canada, December 3, 2015 /PRNewswire/ --
Increasing prevalence of lifestyle disorders and increasing consumer awareness about available treatment options to drive India infertility treatments market
According to recently published Pharmaion report, "India Infertility Treatments Market Opportunities, 2020", infertility treatments market in India is anticipated to grow at a CAGR of over 13% during 2015 - 2020. Growth in the market is anticipated on account of increase in the reproductive age of women, growing marriageable age, increasing use of contraceptives and rising consumption of alcohol and cigarettes. Moreover, adoption of technologies, such as Anti-Mullerian Hormone (AMH) tests, Array Comparative Genomic Hybridization (CGH), Preimplantation Genetic Diagnosis (PGD), and Frozen Embryo Transfer (FET), is proving to be cost effective to the patients, as combination of these technologies with infertility treatments results in improved success rates and reduced risk.
Female infertility dominates the infertility treatments market in India. In 2015, it is estimated that around 30 million Indian couples are suffering from lifetime infertility. In 1990, the Total Fertility Rate (TFR) in India was 3.9%, which declined to 2.3% in 2013. Poor sperm count in males and Polycystic Ovarian Disorder (PCOD) in females are some of the major causes of infertility among Indian population. For curing infertility, three treatments, namely, Fertility Drugs, Surgery, and Assisted Reproductive Treatments (ARTs), are being adopted across the country. Among these treatments, ART dominated the India infertility treatments market in 2014 on account of its capability to manipulate both male sperm as well as female egg coupled with high success rate of the treatment option. Among ART treatments, In Vitro Fertilization (IVF) was the most widely adopted treatment in 2014.
"With growing technological advancements, there has been an increase in the success rate of the infertility treatments. However, some factors restraining the growth of this market in India are low awareness, high cost of treatment and lack of trust among patients. Moreover, the India infertility treatments market is mostly unregulated without any presence of a centralized regulatory body to control the market. Lack of rules and regulations in this field is a serious issue which is anticipated to be addressed by the Indian government during forecast period, thereby attracting many national and international investors." said Mr. Karan Chechi, Research Director with Pharmaion Consultants, a research based global pharmaceutical and healthcare consulting firm.
"India Infertility Treatments Market Opportunities, 2020" has evaluated the future growth potential of infertility treatment market in India and provides statistics and information on market structure, industry behaviour and trends. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyzes the emerging trends along with essential drivers and key challenges faced by the India infertility treatments market.
About Pharmaion
Pharmaion is a research based management consulting firm focused exclusively on Healthcare & Pharmaceutical industry. Led by a team of dynamic industry experts, Pharmaion provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, Pharmaion's clients lead rather than follow market trends. Pharmaion has developed a proprietary database which focuses on identifying the unexplored opportunities in Healthcare and Pharmaceutical industry.
Media Contact
Karan Chechi
Research Director
Contact Phone- +1 646 360 1656
Email- [email protected]
SOURCE Pharmaion
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article